Letter From the Editors
Are We Prepared for the Genomics Era?
By J. Lyle Bootma
-
Letter From the Editors
Are You Ready For Some Ethics, Some Success, Some Cytoprotectants, and Some New Board Members?
By Daniel D. Von Hoff, MD, FACP, and J. Lyle Bootman, PhD
-
Letter From the Editors
Lymphomas – The Diseases That Taught Us Monoclonal Antibodies Can Work
By Daniel D. Von Hoff, MD, FACP, and J. Lyle Bootman, PhD
-
Letter From the Editors
Right Tool, Right Time, Right Reason
By J. Lyle Bootman, PhD, and Daniel D. Von Hoff, MD, FACP
-
Letter to the Editor
AGGRAVATION OF SCHIZOPHRENIA BY CLOMIPRAMINE IN A PATIENT WITH COMORBID OBSESSIVE-COMPULSIVE DISORDER
-
LETTER TO THE EDITOR
GLUCOSE TESTING IN PATIENTS RECEIVING ANTIPSYCHOTIC
-
Reliability and Validity of the Yale-Brown Obsessive-Compulsive Scale in Schizophrenia Patients
Lieuwe de Haan, MD, PhD, Britt Hoogeboom, MD, Nico Beuk, MD, Luuk Wouters, Peter M.A.J. Dingemans, PhD, and Don H. Linszen, MD, PhD
-
Lineamientos universales
Indíce de medicamentos para Latinoamérica
-
Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety and Safety By Matthew T. Morris, Sandip P. Tarpada -
Long-Term Antidepressant Treatment
By Katia K. Delrahim, BA, Rachel Maddux, BA, and Mark Hyman Rapaport, MD
-
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder
By Richard C. Josiassen, John M. Kane, Grace S. Liang, Joshua Burke, Christopher F. O’Brien
-
Long-Term Treatment Strategies in Affective Disorders
By Martin B. Keller, MD
-
Long-Term Treatment Strategies in Anxiety Disorders
By Christer Allgulander, MD, Robert M. A. Hirschfeld, MD, and David J. Nutt, MD, PhD
